Survey of diagnostic and treatment practices for multiple sclerosis in Russian Federation in comparison to European data.

Autor: Boykо A; Pirogov Russian National Research Medical University and Federal Center of Brain research and Neurotechnology of the Federal Medical-Biological Agency of Russia, Moscow, Russian Federation. Electronic address: boykoan13@gmail.com., Fernández O; Institute of Biomedical Research of Malaga (IBIMA), Regional University Hospital and Department of Pharmacology, Faculty of Medicine, University of Malaga, Spain., Alifirova V; Siberian State Medical University, Tomsk, Russian Federation., Babicheva N; Republican Clinical and Diagnostic Center for Demyelinating Diseases, Kazan, Russian Federation., Bakhtiyarova K; Bashkir State Medical University, Ufa, Russian Federation., Volkov A; Pirogov Russian National Research Medical University and Federal Center of Brain research and Neurotechnology of the Federal Medical-Biological Agency of Russia, Moscow, Russian Federation., Glavinskaya N; Sakhalin Regional Clinical Hospital, Yuzhno-Sakhalinsk, Russian Federation., Goncharova Z; Rostov State Medical University, Rostov-on-Don, Russian Federation., Greshnova I; Ulyanovsk Regional Clinical Hospital, Ulyanovsk, Russian Federation., Smagina I; Altai State Medical University, Barnaul, Russian Federation., Lashch N; Pirogov Russian National Research Medical University and Federal Center of Brain research and Neurotechnology of the Federal Medical-Biological Agency of Russia, Moscow, Russian Federation., Inzhinova A; Center of Autoimmune Diseases of the Nervous System of Volgograd Regional Clinical Hospital №3, Volgograd, Russian Federation., Karnaukh V; Amur State Medical Academy, Blagoveshchensk, Russian Federation., Lukashevich I; Chief Neurologist of Chelyabinsk City Administration, Russian Federation., Malkova N; Center of Multiple Sclerosis and Other Autoimmune Diseases, Novosibirsk State Medical University, Novosibirsk, Russian Federation., Poverennova I; Samara State Medical University, Samara, Russian Federation., Sivertseva S; Tyumen Regional Center of Multiple Sclerosis, Tyumen, Russian Federation., Sinitsina L; Neurological Department of State Clinical Hospital №3, Ivanovo, Russian Federation., Khoroshilova N; Regional Clinical Hospital, Orel, Russian Federation., Sherman M; Kirov State Medical University, Kirov, Russian Federation., Shchur S; Interdistrict Department of Multiple Sclerosis, Clinical City Hospital №15, Moscow, Russian Federation., Yampolskaya-Gosteva I; Orenburg Regional Center of Multiple Sclerosis, Regional Clinical Hospital, Orenburg, Russian Federation., Melnikov M; Pirogov Russian National Research Medical University and Federal Center of Brain research and Neurotechnology of the Federal Medical-Biological Agency of Russia, Moscow, Russian Federation. Electronic address: medikms@yandex.ru., Lozovskaya I; RUCTRIMS Office, Russian Federation.
Jazyk: angličtina
Zdroj: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2021 Oct; Vol. 55, pp. 103201. Date of Electronic Publication: 2021 Aug 08.
DOI: 10.1016/j.msard.2021.103201
Abstrakt: Introduction: The data of the survey of European (EU) neurologists on the methods of diagnosis and treatment of multiple sclerosis in Europe were compared with the data of the similar survey of neurologists of the Russian Federation (RF).
Method: Seventy-five neurologists specialized in MS from RF completed questionnaires on radiologically isolated syndrome (RIS), clinically isolated syndrome (CIS), relapsing-remitting (RRMS), secondary progressive (SPMS), and primary progressive (PPMS) multiple sclerosis.
Results: In the case of RIS, only 46% of neurologists from the RF recommended CSF analysis for oligoclonal IgG and only 54.3% performed magnetic resonance imaging (MRI) of the spinal cord, which is significantly lower than in the EU (78% and 80%, respectively). In the case of CIS, significantly more neurologists from the Russian Federation would have tested for antibodies to disorders of the optical spectrum of neuromyelitis (57% in the EU and 94% in the RF). In case of typical RRMS, more neurologists from the RF preferred to start with the second line of disease-modifying therapy (DMT), a lower percentage would choose dimethyl fumarate as the first line DMT (9% in the RF and 25% in the EU). In case of escalating therapy, the majority of EU respondents (68%) indicated that one relapse would be sufficient (only 28% in RF), while in RF, 58% indicated that two relapses would be sufficient (22% in EU). Fewer neurologists from RF would use fingolimod, natalizumab or mitoxantrone for SPMS. 91% of neurologists in RF would like to prescribe ocrelizumab for PPMS.
Conclusion: MS specialists from RF are less active in monitoring RIS than MS specialists from EU. CIS is not indication to use any DMT in RF. MS specialists in RF are more conservative in changing DMT as escalation in cases with breakthrough RRMS. The products without indication to be used in SPMS are rarely prescribed in RF in comparison to EU. Most cases of PPMS in RF would be treated with ocrelizumab.
(Copyright © 2021 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: